Horizon Wealth Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Horizon Wealth Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-440	Closed	-$279K	–	115
2025 Q1	$279K	Sell	440 -51	-10%	-$35.1K	0.05%	80
2024 Q4	$350K	Hold	491	–	–	0.06%	67
2024 Q3	$516K	Hold	491	–	–	0.1%	44
2024 Q2	$516K	Sell	491 -15	-3%	-$14.5K	0.12%	38
2024 Q1	$487K	Buy	506 +15	+3%	+$14.3K	0.13%	43
2023 Q4	$431K	Buy	491 +5	+1%	+$4.12K	0.12%	41
2023 Q3	$400K	Hold	486	–	–	0.16%	42
2023 Q2	$349K	Hold	486	–	–	0.14%	48
2023 Q1	$399K	Sell	486 -14	-3%	-$10.6K	0.3%	37
2022 Q4	$361K	Hold	500	–	–	0.29%	35
2022 Q3	$344K	Hold	500	–	–	0.25%	36
2022 Q2	$296K	Hold	500	–	–	0.12%	76
2022 Q1	$349K	Hold	500	–	–	0.11%	73
2021 Q4	$316K	Buy	+500	New	+$307K	0.09%	85

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Horizon Wealth Management's REGN Position: Q2 2025 in Review

Horizon Wealth Management sold out of Regeneron Pharmaceuticals (REGN) in Q2 2025, closing a stake of 440 shares — an estimated $279K sold.

Horizon Wealth Management first reported a position in REGN in Q4 2021 and held it in 14 quarters. The position peaked at $516K in Q3 2024. 1,202 funds tracked by Wall St. Rank hold REGN as of Q2 2025.

Horizon Wealth Management reported no remaining Regeneron Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Horizon Wealth Management sold 440 Regeneron Pharmaceuticals shares in Q2 2025, an estimated $279K.
Horizon Wealth Management first reported a position in Regeneron Pharmaceuticals in Q4 2021 and held it in 14 quarters.
Horizon Wealth Management's Regeneron Pharmaceuticals position peaked at $516K in Q3 2024.
1,202 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2025.

Based on Horizon Wealth Management's 13F filing for Q2 2025, filed 4 Aug 2025.